{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:37:10Z","timestamp":1793932630493,"version":"4.8.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The combination of immune checkpoint inhibitors and chemotherapy (ICI + Chemo) shows promise in treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), but some patients received limited benefit and the prognostic factors of the treatments remain unclear. Furthermore, ICIs efficacy in subsequent treatments needs further evaluation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic search on PubMed, Embase, the Cochrane Library, and major conference proceedings was conducted to identify relevant studies for meta-analysis. The study was designed to compare ICI + Chemo with chemotherapy in first-line treatment and identify efficacy predictors, and to evaluate ICIs alone in subsequent-line treatment for RM-NPC, with a focus on progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (AEs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifteen trials involving 1928 patients were included. Three trials compared ICI + Chemo with chemotherapy as a first-line treatment, while 12 trials evaluated ICIs alone in subsequent-line treatment of RM-NPC patients. First-line ICI + Chemo showed superior PFS (hazard ratio [HR] = 0.52, 95% confidence interval [CI], 0.43\u20130.63; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt;0.001) and ORR (risk ratio [RR] = 1.14, 95% CI, 1.05\u20131.24; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt;0.001) compared to chemotherapy, without increased AEs (RR = 1.01, 95% CI, 0.99\u20131.03; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.481). Neither programmed death-ligand 1 (PD-L1) nor other factors predicted the efficacy of ICI + Chemo <jats:italic toggle=\"yes\">vs<\/jats:italic>. chemotherapy. Subsequent-line ICIs alone had a median PFS of 4.12 months (95% CI, 2.93\u20135.31 months), an ORR of 24% (95% CI, 20\u201328%), with grade 1\u20135\/grade 3\u20135 AEs at 79%\/14%. However, ICIs alone were associated with significantly shorter PFS (HR = 1.31, 95% CI, 1.01\u20131.68; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.040) than chemotherapy alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>ICI + Chemo confers superior survival benefits compared to chemotherapy in first-line RM-NPC treatment, independent of PD-L1 expression or other factors. However, ICIs alone demonstrate a manageable safety profile but do not surpass chemotherapy in efficacy for subsequent-line treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003371","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T04:00:13Z","timestamp":1731643213000},"page":"531-539","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"138","author":[{"given":"Zhixin","family":"Yu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong 510000, China"},{"name":"Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong 510000, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong 510000, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanye","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong 510000, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichun","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong 510000, China"},{"name":"Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong 510000, China"},{"name":"Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong 510000, China"},{"name":"Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"R1-20250828","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdl320","article-title":"Epidemiology of nasopharyngeal carcinoma in the United States: Improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology","volume":"18","author":"Ou","year":"2007","journal-title":"Ann Oncol"},{"key":"R2-20250828","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers10070210","article-title":"Genomic landscapes of EBV-associated nasopharyngeal carcinoma vs. HPV-associated head and neck cancer","volume":"10","author":"Ngan","year":"2018","journal-title":"Cancers (Basel)"},{"key":"R5-20250828","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"key":"R6-20250828","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R7-20250828","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"R8-20250828","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"key":"R9-20250828","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1200\/JCO.21.00396","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: Final overall survival analysis of GEM20110714 phase III study","volume":"39","author":"Hong","year":"2021","journal-title":"J Clin Oncol"},{"key":"R10-20250828","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/COC.0000000000000449","article-title":"Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma","volume":"41","author":"Larbcharoensub","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"R11-20250828","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.gendis.2021.07.002","article-title":"The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications","volume":"9","author":"Yang","year":"2022","journal-title":"Genes Dis"},{"key":"R12-20250828","first-page":"238","article-title":"Tumour infiltrating lymphocytes in nasopharyngeal carcinoma","volume":"17","author":"Chong","year":"1988","journal-title":"Ann Acad Med Singap"},{"key":"R13-20250828","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"R14-20250828","doi-asserted-by":"crossref","first-page":"CT226","DOI":"10.1158\/1538-7445.AM2022-CT226","article-title":"Abstract ct226: Final progression-free survival analysis of jupiter-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma","volume":"82","author":"Mai","year":"2022","journal-title":"Cancer Res"},{"key":"R15-20250828","doi-asserted-by":"crossref","first-page":"384950","DOI":"10.1200\/JCO.2022.40.36_suppl.384950","article-title":"RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent\/metastatic nasopharyngeal cancer","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"key":"R16-20250828","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R17-20250828","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R18-20250828","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"R19-20250828","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1158\/1078-0432.CCR-21-0822","article-title":"Phase II, randomized study of spartalizumab (PDR001), an anti\u2013PD-1 antibody, versus chemotherapy in patients with recurrent\/metastatic nasopharyngeal cancer","volume":"27","author":"Even","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R20-20250828","doi-asserted-by":"crossref","first-page":"S786","DOI":"10.1016\/j.annonc.2021.08.1268","article-title":"Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC)","volume":"32","author":"Chan","year":"2021","journal-title":"Ann Oncol"},{"key":"R21-20250828","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell\u2013inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"R22-20250828","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"R23-20250828","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"R24-20250828","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"R25-20250828","first-page":"A481","article-title":"A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R26-20250828","doi-asserted-by":"crossref","first-page":"e000437","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: An open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R27-20250828","doi-asserted-by":"crossref","first-page":"e003790","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (captain study)","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R28-20250828","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2019-0284","article-title":"A phase I\/II open-label study of nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors","volume":"24","author":"Ma","year":"2019","journal-title":"Oncologist"},{"key":"R29-20250828","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1200\/JCO.2017.35.15_suppl.6025","article-title":"An open-label, multicohort, phase I\/II study to evaluate nivolumab in patients with virus-associated tumors (checkmate 358): Efficacy and safety in recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC)","volume":"35","author":"Delord","year":"2017","journal-title":"J Clin Oncol"},{"key":"R30-20250828","doi-asserted-by":"crossref","first-page":"S1347","DOI":"10.1016\/j.annonc.2020.10.260","article-title":"Combination ipilimumab and nivolumab in recurrent\/metastatic nasopharyngeal carcinoma (R\/M NPC): Updated efficacy and safety analysis of nct03097939","volume":"31","author":"Kao","year":"2020","journal-title":"Ann Oncol"},{"key":"R31-20250828","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijrobp.2005.06.041","article-title":"Relapse patterns in who 2\/3 nasopharyngeal cancer: Is there a difference between ethnic Asian vs. Non-Asian patients?","volume":"64","author":"Corry","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R32-20250828","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/aje\/kwk008","article-title":"Survival differences by race in nasopharyngeal carcinoma","volume":"165","author":"Sun","year":"2007","journal-title":"Am J Epidemiol"},{"key":"R33-20250828","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R34-20250828","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R35-20250828","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","article-title":"PD-L1 expression in the merkel cell carcinoma microenvironment: Association with inflammation, merkel cell polyomavirus and overall survival","volume":"1","author":"Lipson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"R36-20250828","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"R37-20250828","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2022","journal-title":"J Clin Oncol"},{"key":"R38-20250828","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R39-20250828","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"R40-20250828","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3389\/fonc.2019.01334","article-title":"PD-L1 expression on tumor cells is associated with a poor outcome in a cohort of Caucasian nasopharyngeal carcinoma patients","volume":"9","author":"Minichsdorfer","year":"2019","journal-title":"Front Oncol"},{"key":"R41-20250828","doi-asserted-by":"crossref","first-page":"11720","DOI":"10.3390\/ijms231911720","article-title":"Analysis of Epstein-Barr virus (EBV) and PD-L1 expression in nasopharyngeal carcinoma patients in a non-endemic region","volume":"23","author":"Dias","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R42-20250828","doi-asserted-by":"crossref","first-page":"43627","DOI":"10.1038\/srep43627","article-title":"PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"R43-20250828","doi-asserted-by":"crossref","first-page":"e0157969","DOI":"10.1371\/journal.pone.0157969","article-title":"Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma","volume":"11","author":"Lee","year":"2016","journal-title":"PLoS One"},{"key":"R44-20250828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12935-019-0863-5","article-title":"The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"19","author":"Huang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"R45-20250828","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"R46-20250828","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12935-021-02217-y","article-title":"Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"R47-20250828","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12935-021-02162-w","article-title":"Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes","volume":"21","author":"Luo","year":"2021","journal-title":"Cancer Cell Int"},{"key":"R48-20250828","doi-asserted-by":"crossref","first-page":"e002014","DOI":"10.1136\/jitc-2020-002014","article-title":"Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma","volume":"9","author":"Ma","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R49-20250828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40425-019-0636-7","article-title":"Comparative safety and efficacy of anti-pd-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: Findings from recent advances in landmark trials","volume":"7","author":"Lv","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R50-20250828","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.medj.2022.07.009","article-title":"Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma","volume":"3","author":"You","year":"2022","journal-title":"Med"},{"key":"R51-20250828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.lungcan.2020.10.017","article-title":"Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC","volume":"150","author":"Bishnoi","year":"2020","journal-title":"Lung Cancer"},{"key":"R52-20250828","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/cncr.33270","article-title":"Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials","volume":"127","author":"Wang","year":"2021","journal-title":"Cancer"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:01:19Z","timestamp":1756393279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003371","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"2024-06-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}